Haeussler J - Search Results

1

A pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathy.

Schwartz S, Etropolski MS, Shapiro DY, Rauschkolb C, Vinik AI, Lange B, Cooper K, Van Hove I, Haeussler J. Schwartz S, et al. Among authors: haeussler j. Clin Drug Investig. 2015 Feb;35(2):95-108. doi: 10.1007/s40261-014-0249-3. Clin Drug Investig. 2015. PMID: 25503082 Free PMC article.

2

Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study.

Afilalo M, Etropolski MS, Kuperwasser B, Kelly K, Okamoto A, Van Hove I, Steup A, Lange B, Rauschkolb C, Haeussler J. Afilalo M, et al. Among authors: haeussler j. Clin Drug Investig. 2010;30(8):489-505. doi: 10.2165/11533440-000000000-00000. Clin Drug Investig. 2010. PMID: 20586515 Clinical Trial.

3

Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial.

Schwartz S, Etropolski M, Shapiro DY, Okamoto A, Lange R, Haeussler J, Rauschkolb C. Schwartz S, et al. Among authors: haeussler j. Curr Med Res Opin. 2011 Jan;27(1):151-62. doi: 10.1185/03007995.2010.537589. Curr Med Res Opin. 2011. PMID: 21162697 Clinical Trial.

4

A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain.

Daniels SE, Upmalis D, Okamoto A, Lange C, Häeussler J. Daniels SE, et al. Among authors: haeussler j. Curr Med Res Opin. 2009 Mar;25(3):765-76. doi: 10.1185/03007990902728183. Curr Med Res Opin. 2009. PMID: 19203298 Clinical Trial.

5

Safety and efficacy of fulranumab in osteoarthritis of the hip and knee: results from four early terminated phase III randomized studies.

Kelly KM, Sanga P, Zaki N, Wang S, Haeussler J, Louie J, Thipphawong J. Kelly KM, et al. Among authors: haeussler j. Curr Med Res Opin. 2019 Dec;35(12):2117-2127. doi: 10.1080/03007995.2019.1653068. Epub 2019 Sep 13. Curr Med Res Opin. 2019. PMID: 31387410 Clinical Trial.

6

Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain.

Sanga P, Katz N, Polverejan E, Wang S, Kelly KM, Haeussler J, Thipphawong J. Sanga P, et al. Among authors: haeussler j. Pain. 2013 Oct;154(10):1910-1919. doi: 10.1016/j.pain.2013.05.051. Epub 2013 Jun 5. Pain. 2013. PMID: 23748114 Clinical Trial.

7

Long-Term Safety and Efficacy of Fulranumab in Patients With Moderate-to-Severe Osteoarthritis Pain: A Phase II Randomized, Double-Blind, Placebo-Controlled Extension Study.

Sanga P, Katz N, Polverejan E, Wang S, Kelly KM, Haeussler J, Thipphawong J. Sanga P, et al. Among authors: haeussler j. Arthritis Rheumatol. 2017 Apr;69(4):763-773. doi: 10.1002/art.39943. Epub 2017 Mar 8. Arthritis Rheumatol. 2017. PMID: 27748055 Clinical Trial.

8

The Potential Role of Sensory Testing, Skin Biopsy, and Functional Brain Imaging as Biomarkers in Chronic Pain Clinical Trials: IMMPACT Considerations.

Smith SM, Dworkin RH, Turk DC, Baron R, Polydefkis M, Tracey I, Borsook D, Edwards RR, Harris RE, Wager TD, Arendt-Nielsen L, Burke LB, Carr DB, Chappell A, Farrar JT, Freeman R, Gilron I, Goli V, Haeussler J, Jensen T, Katz NP, Kent J, Kopecky EA, Lee DA, Maixner W, Markman JD, McArthur JC, McDermott MP, Parvathenani L, Raja SN, Rappaport BA, Rice ASC, Rowbotham MC, Tobias JK, Wasan AD, Witter J. Smith SM, et al. Among authors: haeussler j. J Pain. 2017 Jul;18(7):757-777. doi: 10.1016/j.jpain.2017.02.429. Epub 2017 Feb 27. J Pain. 2017. PMID: 28254585 Free PMC article. Review.

9

Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss.

Trouillot TE, Pace DG, McKinley C, Cockey L, Zhi J, Häeussler J, Guerciolini R, Showalter R, Everson GT. Trouillot TE, et al. Among authors: haeussler j. Am J Gastroenterol. 2001 Jun;96(6):1888-94. doi: 10.1111/j.1572-0241.2001.03783.x. Am J Gastroenterol. 2001. PMID: 11421247 Clinical Trial.

10

Low levels of natural IgM antibodies against phosphorylcholine are independently associated with vascular remodeling in patients with coronary artery disease.

Gleissner CA, Erbel C, Haeussler J, Akhavanpoor M, Domschke G, Linden F, Doesch AO, Conradson G, Buss SJ, Hofmann NP, Gitsioudis G, Katus HA, Korosoglou G. Gleissner CA, et al. Among authors: haeussler j. Clin Res Cardiol. 2015 Jan;104(1):13-22. doi: 10.1007/s00392-014-0750-y. Epub 2014 Aug 8. Clin Res Cardiol. 2015. PMID: 25103819

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

16 results

Search Page